Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS

Detalhes bibliográficos
Autor(a) principal: Fávero,Francis Meire
Data de Publicação: 2017
Outros Autores: Voos,Mariana Callil, Castro,Isac de, Caromano,Fátima Aparecida, Oliveira,Acary Souza Bulle
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos de neuro-psiquiatria (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2017000800515
Resumo: ABSTRACT Objective To investigate the impact of epidemiological and clinical factors on the benefit of riluzole in patients with amyotrophic lateral sclerosis (ALS). Methods The survival rate of 578 patients with ALS (1999-2011) was analyzed by descriptive statistics and Kaplan-Meier curves. Considering the median of the sample survival time (19 months), patients were divided in two groups: below (B19) and above the median (A19). Kaplan-Meier curves compared the survival rates of patients treated with riluzole and with patients who did not take the medication. Results Riluzole increased the survival rates of patients with lower limb onset who were diagnosed after the first appointment in B19. Patients with bulbar onset and diagnosed on the first, or after the first appointment showed higher survival rates in A19. Males lived longer than females in both groups. Conclusion Epidemiological and clinical factors influenced the benefit of riluzole in the survival rates of patients with ALS.
id ABNEURO-1_af45249a916fb603f07a228fb039840d
oai_identifier_str oai:scielo:S0004-282X2017000800515
network_acronym_str ABNEURO-1
network_name_str Arquivos de neuro-psiquiatria (Online)
repository_id_str
spelling Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALSepidemiologyamyotrophic lateral sclerosismotor neuron diseasesurvivalriluzoleABSTRACT Objective To investigate the impact of epidemiological and clinical factors on the benefit of riluzole in patients with amyotrophic lateral sclerosis (ALS). Methods The survival rate of 578 patients with ALS (1999-2011) was analyzed by descriptive statistics and Kaplan-Meier curves. Considering the median of the sample survival time (19 months), patients were divided in two groups: below (B19) and above the median (A19). Kaplan-Meier curves compared the survival rates of patients treated with riluzole and with patients who did not take the medication. Results Riluzole increased the survival rates of patients with lower limb onset who were diagnosed after the first appointment in B19. Patients with bulbar onset and diagnosed on the first, or after the first appointment showed higher survival rates in A19. Males lived longer than females in both groups. Conclusion Epidemiological and clinical factors influenced the benefit of riluzole in the survival rates of patients with ALS.Academia Brasileira de Neurologia - ABNEURO2017-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2017000800515Arquivos de Neuro-Psiquiatria v.75 n.8 2017reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/0004-282x20170083info:eu-repo/semantics/openAccessFávero,Francis MeireVoos,Mariana CallilCastro,Isac deCaromano,Fátima AparecidaOliveira,Acary Souza Bulleeng2017-09-20T00:00:00Zoai:scielo:S0004-282X2017000800515Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2017-09-20T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse
dc.title.none.fl_str_mv Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS
title Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS
spellingShingle Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS
Fávero,Francis Meire
epidemiology
amyotrophic lateral sclerosis
motor neuron disease
survival
riluzole
title_short Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS
title_full Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS
title_fullStr Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS
title_full_unstemmed Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS
title_sort Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS
author Fávero,Francis Meire
author_facet Fávero,Francis Meire
Voos,Mariana Callil
Castro,Isac de
Caromano,Fátima Aparecida
Oliveira,Acary Souza Bulle
author_role author
author2 Voos,Mariana Callil
Castro,Isac de
Caromano,Fátima Aparecida
Oliveira,Acary Souza Bulle
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Fávero,Francis Meire
Voos,Mariana Callil
Castro,Isac de
Caromano,Fátima Aparecida
Oliveira,Acary Souza Bulle
dc.subject.por.fl_str_mv epidemiology
amyotrophic lateral sclerosis
motor neuron disease
survival
riluzole
topic epidemiology
amyotrophic lateral sclerosis
motor neuron disease
survival
riluzole
description ABSTRACT Objective To investigate the impact of epidemiological and clinical factors on the benefit of riluzole in patients with amyotrophic lateral sclerosis (ALS). Methods The survival rate of 578 patients with ALS (1999-2011) was analyzed by descriptive statistics and Kaplan-Meier curves. Considering the median of the sample survival time (19 months), patients were divided in two groups: below (B19) and above the median (A19). Kaplan-Meier curves compared the survival rates of patients treated with riluzole and with patients who did not take the medication. Results Riluzole increased the survival rates of patients with lower limb onset who were diagnosed after the first appointment in B19. Patients with bulbar onset and diagnosed on the first, or after the first appointment showed higher survival rates in A19. Males lived longer than females in both groups. Conclusion Epidemiological and clinical factors influenced the benefit of riluzole in the survival rates of patients with ALS.
publishDate 2017
dc.date.none.fl_str_mv 2017-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2017000800515
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2017000800515
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0004-282x20170083
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
dc.source.none.fl_str_mv Arquivos de Neuro-Psiquiatria v.75 n.8 2017
reponame:Arquivos de neuro-psiquiatria (Online)
instname:Academia Brasileira de Neurologia
instacron:ABNEURO
instname_str Academia Brasileira de Neurologia
instacron_str ABNEURO
institution ABNEURO
reponame_str Arquivos de neuro-psiquiatria (Online)
collection Arquivos de neuro-psiquiatria (Online)
repository.name.fl_str_mv Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia
repository.mail.fl_str_mv ||revista.arquivos@abneuro.org
_version_ 1754212782696300544

Registros relacionados